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To Leon and Fiamma, with love
You travel to search and you come back home to find yourself there
Chimamanda Ngozi Adichie
Keep Ithaka always in your mind.
Arriving there is what you’re destined for.
But don’t hurry the journey at all.
Better if it lasts for years,
so you’re old by the time you reach the island,
wealthy with all you’ve gained on the way,
not expecting Ithaka to make you rich.
Ithaka gave you the marvelous journey.
Without her you wouldn’t have set out.
She has nothing left to give you now.
And if you find her poor, Ithaka won’t have fooled you.
Wise as you will have become, so full of experience,




The ovarian reserve is defined as the number of eggs embodied in primordial follicles. 
Every woman is born with a fixed number of primordial follicles, which are formed 
during fetal development. Pathological events can affect the ovarian reserve both pre- 
and postnatally and cause a premature ovarian insufficiency (POI), i.e. a precocious 
exhaustion of the endocrine and reproductive potential of the ovaries. In prenatal life, 
intrauterine growth restriction (IUGR) caused by poor maternal nutrition or insufficient 
placental flow to the fetus, has been associated with alterations in pubertal development 
and follicle number in animals and humans, with inconclusive evidence. In postnatal life, 
major iatrogenic causes of POI are chemo- and radiotherapeutic treatments administered 
to cancer patients. Fertility preservation strategies, such as ovarian tissue cryopreserva-
tion (OTC), are of fundamental importance to preserve fertility in these patients. These 
procedures are still experimental and in continuous evolution as more data are acquired. 
In this thesis, we aimed at investigate the impact of IUGR on ovarian follicles and 
gene expression in neonatal, juvenile and peripubertal rats, using a model of surgically-
induced placental insufficiency. Secondly, we focused on the effects of chemotherapy 
exposure on ovarian follicles and stroma in ovarian tissues from cancer patients who 
underwent OTC for fertility preservation purposes. Additionally, we analyzed the effi-
cacy of fertility preservation criteria in selecting the patients at high risk of infertility, by 
analysis of ovarian function during follow-up, the fruition rate and the timing of OTC 
in a large pediatric oncology unit in Finland. Timing of OTC was analyzed in relation 
to exposure to chemotherapy.
A reduced primordial and total follicle count was found in the ovaries of neonate and 
juvenile rats. Follicle count normalized at peripubertal ages, alongside with the recovery 
of body weight. The expression of 24 genes was modified in the rat ovaries in response 
to the placental insufficiency. We interpreted the gene reprogramming as compensa-
tory, possibly explaining the recovery of follicle number (by a downregulation of the 
physiological rates of follicle activation and/or depletion). The gene modifications could 
also have unknown long-term consequences on ovarian function, whose definition was 
beyond the aims of this work. An increased number of atretic follicles and a reduced size 
and number of residual intact follicles were evidenced in the ovaries of patients exposed 
to chemotherapy before OTC. Exposure to chemotherapy also reduced the secretion 
of steroid hormones in culture and damaged the ovarian stroma, by increasing colla-
gen deposition and apoptosis. Finally, analysis of OTC data from Helsinki Children’s 
Hospital revealed that patients at high risk of infertility were correctly identified by the 
selection criteria, despite fruition rate was not optimal. We observed an increased risk 
of ovarian failure in older patients, which is in line with the age-related decline of the 
ovarian reserve. We also reported longer time frames between indication to OTC and 
execution of the procedure in patients with malignant diseases, which was associated 
to increased exposure to alkylating agents. Delays in the execution of OTC should 
be limited in order to avoid further damage to the ovarian tissue as a consequence of 
chemotherapy exposure, especially in older patients.
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The mammalian ovary is a highly organized organ that harbors the female  gametes 
and provide fertilizable oocytes throughout the reproductive lifespan. The ovary 
also produces sex steroid hormones that support the oocyte maturation, the 
development of female secondary sexual characteristics and the establishment of 
pregnancy after oocyte fertilization. Genetic and environmental factors can affect 
the ovarian reserve, defined as the non-renewable pool of immature oocytes sur-
rounded by flattened granulosa cells (GCs) forming the primordial follicles (PFs), 
the basic functional unit of the ovary. The precocious exhaustion of the ovarian 
reserve is known as premature ovarian insufficiency (POI) and can derive from 
the exposure to insults during the life of an individual, starting from fetal life. Any 
insult that alters the fetal environment leads to adaptive responses of the fetus that 
often translate into diseases in later life. Exposure to environmental chemicals, 
drugs, infections, poor or excessive maternal nutrition and placental dysfunction 
have been shown to be detrimental to the fetal ovary [1]. In postnatal life, gonado-
toxic therapies are the most relevant iatrogenic causes of POI, which is becoming 
increasingly important given the growing number of long-term childhood cancer 
survivors. Fertility preservation methods have been developed during the last 
decades to spare fertility in patients treated with gonadotoxic cancer therapies.
This thesis describes the consequences of two different environmental insults 
on the ovarian reserve: placental insufficiency during fetal life in rat ovaries and 
chemotherapy treatment during childhood and adolescence in human ovarian tissues 
harvested for fertility preservation. In addition, we investigated the appropriate-
ness of the selection criteria for fertility preservation in children and the efficacy 
of their implementation. 
1.1 Ovarian physiology in humans and rodents
1.1.1 Oogenesis
At birth the mammalian ovary contains a finite number of oocytes enclosed into 
PFs. In humans and rodents, the oocytes arise during fetal life from primordial 
germ cells (PGCs). These cells reside in the extra-embryonic mesoderm and 
migrate to the genital ridge at around 5-6 weeks of fetal development in humans 
[2, 3] and between 9 and 10.5 days post-conception (dpc) in mice [4]. The gonad 
is ‘bipotential’ until week 7 in humans and 11.5 dpc in mice. Subsequently, PGCs 
differentiate into oogonia and the gonad becomes an ovary in the process called sex 
differentiation. These events can take place in the absence of the sex-determining 
region on the Y chromosome (SRY) gene and under the drive of female-specific 
genes, such as forkhead box L2 (FOXL2), wingless-type MMTV integration site 
family, member 4 (WNT4) and follistatin (FST) [1]. From week 7 in humans and 
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from 10.5 dpc in mice, the oogonia undergo multiple divisions by mitosis and 
start to arrange in cyst-like clusters known as germ cell cysts, structures contain-
ing pre-granulosa cells and germ cells [1, 5]. The oogonia enter the first steps of 
meiosis by 13.5 dpc in mice and week 10 of gestation in humans and become 
oocytes. Oocytes proceed through prophase I of meiosis and arrest at the diplo-
tene stage, remaining quiescent until ovulation [1, 5]. A large number of oocytes 
undergo cell death during this phase. In mice two main waves of apoptosis have 
been documented, between 13.5 and 15.5 dpc and from 17.5 dpc until the day of 
birth, when cyst breakdown takes place allowing the assembly of PFs. In humans, 
waves of germ cell apoptosis occur during midgestation, with highest rates between 
14 and 28 weeks. Cyst breakdown starts at 20 weeks of gestation, determining the 
formation of PFs already during fetal life in humans [1] (Figure 1).
Figure 1. Timelines of major events during ovarian fetal development in mouse and human. 
Redrawn based on [1].
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As a result of these complex processes of cell proliferation and apoptotic depletion, 
the number of oocytes in humans decline from several million at around five months 
of gestational age to less than 1 million at birth. This is followed by a continuous 
decline in the number of PFs that will be depleted by apoptosis until the age of 
menopause, that occurs at around 50 years of age, when only 1000  follicles are 
left in the ovaries [6]. In the rat ovary, around two-thirds of the oocytes are loss 
from the onset of meiosis until two days after birth [7].
1.1.2 Folliculogenesis
The age-related decline of PFs in postnatal life occurs as a result of different 
processes: the follicles can be depleted already in their quiescent state or they 
can start to mature and then undergo apoptosis at different stages during their 
development. Around 1000 follicles are lost every month until 37 years of age 
and then the decay accelerates until the pool is almost completely depleted and 
menopause occurs [8, 9]. 
During childhood the ovary is quiescent and oocytes within PFs are arrested in 
the diplotene stage of meiosis I. The PFs at this stage are defined as non-growing 
(NGF) or dormant follicles. Although no ovulation will occur until puberty, PFs 
are already activated and grow up to the antral stage in childhood. Antral follicles 
have been described throughout infancy and childhood in human ovaries [10] and 
during the early infantile period (postnatal day (PND) 8-14) in rats and mice [7, 
11]. The developmental dynamics of PFs have been the subject of recent studies in 
mice. These studies led to the identification of two different classes of PFs: a ‘first 
wave’ and an ‘adult wave’. The ‘first wave’ is activated immediately after birth, 
persists in the mouse ovary up to ~ 3 months of age and appears to be  responsible 
for the onset of puberty and for the early fertility. The ‘adult wave’ of PFs is acti-
vated gradually during reproductive life and provides fertility until the end of the 
reproductive life [12-14] (Figure 2). Structural and dynamic differences in the 
PFs have been observed also in humans. A study from Anderson et al. reported 
the presence of morphologically abnormal PFs in prepubertal human ovaries that 
were absent in adult ovaries, and could represent the human equivalent of the first 
wave identified in mice studies [15]. 
With the activation of the hypothalamic-pituitary-gonadal (HPG) axis at puberty, 
under the drive of gonadotropins, one oocyte is selected at every cycle to com-
plete meiosis I and be ovulated. After ovulation the oocyte remains arrested in 
metaphase of meiosis II until fertilization.
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From the activation of a PF to the ovulation, the oocyte and the follicle undergo 
dramatic morphological changes in the process known as folliculogenesis. The 
recruitment of NGF into the growing pool is marked by the proliferation and differ-
entiation of the surrounding pre-granulosa cells followed by a remarkable growth of 
the oocyte [8]. Pre-granulosa cells shift from flattened to cuboidal shape and studies 
have shown that the oocyte growth starts when a critical number of cuboidal GCs 
is reached, that is 10 cuboidal cells in mice [16] and 15 cuboidal cells in humans 
[17]. When a complete layer of cuboidal GCs surrounds the oocyte, it becomes a 
primary	follicle.	The	follicle	diameter	increases	from	40	μm	to	50-60	μm	during	this	
transition [18]. At this stage, a zona pellucida is formed around the oocyte and GCs 
proliferate building multiple layers, marking the transition into secondary follicles 
(80-100	μm	in	early	stage)	[9].	The	secondary	follicles	receive	blood	supply	by	
one or two arterioles, becoming exposed to the blood circulation [19]. When the 
follicles	contain	three	to	six	layers	of	GCs	(103-163	μm),	stromal	cells	near	the	
basal lamina align parallel to each other and differentiate into theca cells (TCs) 
marking the transition into a preantral follicle. Subsequently, antral (or tertiary) 
follicles develop following the formation of small antral cavities filled with fluid 
that	progressively	aggregate	to	form	a	single	antrum	(180-250	μm).	The	antral	
follicles enlarge by further proliferation of GCs and increase of the antrum’s size 
until they reach a diameter of 2 mm. From this stage onwards, follicles become 
selectable for ovulation. Most of these follicles undergo atresia, whereas the fol-
licle selected for ovulation continues to grow and increases its size up to 20 mm 
in humans [9] (Figure 3). 
Figure 2. The two waves of follicles traced by tamoxifen-inducible reporters specific of 
primordial follicles, Foxl2 for the first wave and Sohlh1 for the adult wave. Adapted with 
permission from [14].
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Figure 3. Schematic representation of follicle development in the human ovary. Reproduced 
with permission from [9].
Follicles in the antral stage have about the same size in rats and humans, whereas 
pre-ovulatory follicles in rats are only 0.9-1.0 mm in diameter [20]. Under the 
drive of the midcycle gonadotropin surge, the follicles increase their progesterone 
production and start to luteinize. This process ultimately leads to ovulation through 
the rupture of the follicle wall and the release of the oocyte [9, 21]. Luteinization 
of the GCs and TCs defines the formation of a corpus luteum that will be respon-
sible for progesterone secretion during the second half of the menstrual cycle. 
If pregnancy occur, the human chorionic gonadotropin (HCG) will maintain the 
corpus luteum and production of progesterone by GCs will support the early stages 
of pregnancy. In the absence of fertilization the corpus luteum will involute into 
a corpus albicans and eventually be absorbed. 
The above described process of folliculogenesis is regulated by the two gonado-
tropins secreted from the pituitary, follicle-stimulating hormone (FSH) and lute-
inizing hormone (LH), under the control of the hypothalamic gonadotropin-releasing 
factor (GnRH) and ovarian factors such as activin and inhibin. Although preantral 
follicle growth is gonadotropin-independent, FSH promotes follicle growth also 
at preantral stages and is necessary for the formation of antral follicles. From the 
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antral stage, FSH sustains follicle growth, stimulates estradiol production by GCs 
and induces expression of LH receptors in GCs [22]. With the progression of the 
follicle growth, the sensitivity of GCs to FSH decline simultaneously with increasing 
sensitivity to LH, which maintains follicle growth and allows lute inization upon 
LH surge [21]. During follicular growth LH stimulates the production of andro-
gens from TCs and the expression of aromatase in GCs, thus doubly contributing 
to estrogens production [21, 22]. 
1.1.3 Regulation of primordial follicle activation
The activation of PFs, that marks their entry into the growing phase from the 
dormant stage, is not yet completely understood. In particular, a major challenge 
is to understand the factors that regulate PFs’ fate towards activation rather than 
quiescence or apoptosis. Two main signaling pathways involved in PF activation 
and tightly interconnected with each other have been intensively investigated in 
recent years, the phosphatidylinositol 3 kinase (PI3K) pathway and the mammalian 
target of rapamycin (MTOR) pathway (Figure 4).
Figure 4. Schematic illustration of PI3K/PTEN/AKT and MTOR signaling pathways in 
the mammalian ovary.
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The PI3K pathway is constituted by different members including phosphatases, 
kinases and transcription factors and it is involved in processes of cell prolifera-
tion and survival in all organs and tissues [8]. Upon binding of different ligands 
(such as insulin and growth factors) with the respective receptors located on the 
cell membrane, PI3K activates and converts phosphatidylinositol-4,5-bisphosphate 
(PIP2) into phosphatidylinositol-3,4,5-trisphosphate (PIP3). The latter molecule acts 
as a messenger and recruits the phosphoinositide-dependent protein kinase (PDK) 
to phosphorylate protein kinase B (AKT). The AKT is a serine/threonine kinase 
that can in turn phosphorylate many substrates. Among those, a crucial one is the 
forkhead box O3A (FOXO3A) [8]. FOXO3A is a transcription factor residing in 
the cell nucleus in its unphosphorylated state and is translocated into the cyto-
plasm upon phosphorylation thereby losing its transcriptional function. Studies in 
mice models have demonstrated that FOXO3A is expressed in the nucleus of PFs 
and becomes downregulated as soon as the PFs start to grow and transform into 
primary follicles [23]. Moreover FOXO3A knock-out in mice resulted in massive 
activation of PFs, followed by depletion and precocious exhaustion of the PF 
reserve [24]. Thus, FOXO3A acts as a suppressor of PF activation by transcrip-
tional control of genes involved in apoptosis and cell cycle arrest in the oocyte 
nucleus. Another key molecule of the PI3K pathway is the phosphatase and tensin 
homolog (PTEN) that regulates the PI3K pathway by inhibition of PI3K, thereby 
contributing to the suppression of PF activation. Indeed, deletion of PTEN in mice 
oocytes also resulted in premature activation and depletion of the entire PF pool 
[25]. Other two well-defined substrates of AKT are the tuberin/tuberous sclerosis 
complexes 1 and 2 (TSC1 and TSC2) that are inactivated upon phosphorylation 
by AKT. Inactivated TSCs cannot longer suppress mTOR, which subsequently 
activates downstream molecules such as ribosomal protein S6 kinase (S6K) and 
ribosomal protein S6 (RPS6), responsible for translation of proteins involved in 
cell survival and growth. Deletion of both TSCs from the oocytes of mice PFs 
produced the premature activation and depletion of all PFs [26, 27]. The role of 
several other molecules in the maintenance of PFs dormancy has been elucidated 
[28]. Among them, anti-Müllerian hormone (AMH) secreted by growing follicles 
[29] and FOXL2 expressed in pre-granulosa cells of PFs play an important role 
in maintaining the quiescence of PFs [30]
1.1.4 Postnatal developmental stages and hormonal patterns in 
rats and humans
The neonatal period corresponds to PND 0-7 in rats and to the first month of life 
in humans. During this period a transient activation of the hypothalamic-pituitary-
gonadal (HPG) axis causes a rise of gonadotropins that peaks at PND 12 in rats 
(infantile period) and between 1 week and 3 months of age in humans [31]. This 
neonatal surge marks the so-called mini-puberty, which corresponds also to an 
increase in circulating sex steroid hormones, with preponderance of estradiol in 
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females and testosterone, inhibin B and AMH in males. In humans, the HPG axis 
then enters a quiescent phase during which gonadotropins’ levels approach the 
zero. On the contrary, in rats, although FSH and LH significantly decline during 
the juvenile period, they never reach zero and a pulsatile activity of LH begins 
already at around PND 24 and rises progressively until puberty onset. FSH levels 
increase only after PND 35 when the peripubertal stage starts in rats. Detailed 
frames of postnatal development in rats and humans are presented in Table 1.
Table 1. Time frames of postnatal development in rats and humans. Adapted with 
permission from [32].
Stage Rats Humans
Neonatal 0-6 PND 0-1 mo
Infantile 7-17 PND 2 mo - 2 y
Juvenile 18-34 PND 3-9 y
Peripubertal 35-42 PND 10-15 y
Late adolescent 43-70 PND 16-21 y
1.2 Effects of intrauterine growth restriction (IUGR) on 
the female reproductive organs 
1.2.1 IUGR and the Developmental Origins of Health and Disease 
The term IUGR describes an impairment of growth occurring during fetal life and 
can be caused by maternal and environmental factors, such as chronic  undernutrition, 
placental insufficiency, infections, and other toxic exposures. When IUGR occurs, 
the newborn will often be small for gestational age (SGA) at birth, defined as 
a weight and/or length at birth of at least 2 SD below the mean for gestational 
age. SGA is often improperly used as a synonym for IUGR, although the term 
also includes newborns who are constitutionally small and whose growth has not 
been compromised during fetal life. During the late ´80s the retrospective cohort 
studies of Barker and Hales showed a significant association between patterns of 
fetal growth and risk of diseases later in life, such as type 2 diabetes and cardio-
vascular diseases. Many studies in the following decades confirmed these find-
ings, giving origin to the so called Developmental Origins of Health and Disease 
(DOHaD) hypothesis. According to the hypothesis, when the fetus is exposed to 
an inadequate supply of oxygen and/or nutrients, survival of vital organs, such as 
brain, is preserved at the expense of whole body growth and development of other 
organs. In response to this, the organism actuates adaptive responses, which are 
driven by changes in gene expression, in a process known as fetal programming. 
However, in postnatal life, the adaptive genetic asset clashes with an adequate 
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or even opposite environment, resulting in an increased susceptibility to various 
diseases. Experimental studies have provided evidence of the fetal programming 
of gene expression as a consequence of IUGR in many organs and tissues.
Fetal life is a critical window of exposure for the reproductive system and although 
differences exist between humans and animals used in experimental studies, such 
animal models are extremely useful in assessing the risk of exposure to  pathological 
events on key human reproductive and developmental processes. An insufficient 
blood and/or nutrient supply to the fetus can induce a reprogramming of the endo-
crine axes and a change in endocrine set points that will persist throughout life. 
Moreover, as gametogenesis takes place during fetal life, an altered fetal environ-
ment may affect gonadal development and function, having a potential impact on 
future fertility and/or on the quality of gametes.
1.2.2 Human studies 
Some epidemiological studies have focused on long-term health outcomes in 
 children born SGA, as surrogate measure of IUGR. In terms of pubertal develop-
ment, the results are controversial and difficult to compare for the variability of 
selection criteria and outcome measures. However, most of the studies concluded 
that puberty in SGA children begins relatively early but within the normal range 
and at a shorter height compared to children born with a normal weight/length 
[33]. This seems to be particularly true for the small percentage of SGA children 
who fail in attaining catch-up growth during postnatal life [34]. A lower number of 
primordial follicles has been observed in the ovaries of severely growth-restricted 
fetuses who died between 20 and 40 weeks of gestation because of placental 
insufficiency [35] and smaller ovaries and uterus and a reduced ovulation rate 
have been reported in post-menarcheal girls born SGA [36, 37]. The influence of 
IUGR on future fertility is still controversial. An association between IUGR and 
risk of infertility was reported in a study including women selected from infertility 
 clinics [38]. SGA women did not have a longer time to pregnancy as compared to 
AGA women in a questionnaire-based study [39] and in another recent publica-
tion including more than 10,000 men and women, a higher risk of infertility was 
found in SGA men but not in SGA women [40]. 
1.2.3 Animal studies 
Animal models are a fundamental tool to infer data relevant to human diseases 
and have been extensively used to explore the consequences of IUGR in various 
organs and tissues. Several experimental models have been designed to restrict 
fetal growth [41, 42]. Prenatal nutrient manipulation is the most common approach, 
whereas uterine arteries ligature is the most frequently used among surgical 
 models. Uterine arteries ligature produces a reduction of the placental blood flow 
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to the fetuses that mimics the pathogenetic mechanism of placental insufficiency 
in human pregnancies. This model is particularly relevant to study human fetal 
growth restriction in developed countries, where a reduced placental blood flow 
is the most frequent cause of IUGR [43]. Most of the data generated from animal 
models have focused on the metabolic effects of IUGR whereas only a few studies 
have investigated the impact on the reproductive system. DNA damage in fetal 
oogonia and altered folliculogenesis have been described after IUGR induced by 
maternal undernutrition in murine and ovine models [44-46]. Only two studies 
using uterine arteries ligature reported a reduced number of follicles and delayed 
onset of puberty in adult IUGR female rats compared to controls [47, 48]. 
1.3 Effects of cancer treatments on the female 
 reproductive organs
Over the past five decades the percentage of children surviving cancer has dra-
matically increased. According to the last reports, the 5-year survival rate after a 
cancer diagnosis has exceeded the 80% among children and young adolescents 
in Europe and in the USA [49]. As a result of the increased life expectancy, many 
more children are becoming adult survivors and facing the chronic consequences 
of cancer treatments. In females, one of the major late effects of cancer treatments 
is premature ovarian insufficiency (POI). POI is characterized by the precocious 
exhaustion of the ovarian follicles that leads to premature menopause and  infertility. 
Clinically POI is characterized by different features according to the patient’s 
pubertal development at the onset of POI: i) lack of pubertal onset in prepubertal 
girls (absent Tanner stage 2 breast development by age 13), ii) lack of pubertal 
progression in pubertal girls, iii) absent menarche by age 16 (primary  amenorrhea) 
in pre-menarcheal patients, iv) disappearance of menstrual cycles (secondary 
amenorrhea)	for	≥	4	months	in	post-menarcheal	girls.	These	clinical	features	are	
accompanied by elevated gonadotropins and low levels of estrogens, AMH and 
inhibin. Twice elevated serum levels of FSH in the menopausal range (usually 
> 25 IU/l) support the diagnosis of POI [50]. A report from the childhood cancer 
survivor study (CCSS) in 2006 estimated that the risk of POI in childhood cancer 
survivors is increased compared to their siblings, with a cumulative incidence of 
8% by age 40 years [51]. More recently, Barton and co-workers analyzed data 
from 3,531 female cancer survivors and 1,366 unaffected siblings enrolled in the 
CCSS and found that 16% of the survivors experienced infertility, correspond-
ing to a relative risk of 1.54, compared to siblings. Among them, 64% eventually 
achieved a pregnancy, even though with an increased time to pregnancy [52].
The entity of ovarian damage varies according to two main variables: the patient 
age and the type of treatment. 
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1.3.1 Age
Studies have shown that the likelihood of severe ovarian failure following cancer 
treatments increases with the age of the patient [53]. This is in agreement with 
the physiological decline in the number of PFs with age, well shown by predic-
tion models of the ovarian reserve [6]. The higher the amount of PFs at start of 
gonadotoxic treatments, the less severe will be the damage. However, variations 
in the amount of PFs present at birth as well as genetic polymorphisms likely play 
an important role in the individual susceptibility to damage [54]. 
1.3.2 Chemotherapy
The gonadotoxic potential of chemotherapeutic agents is determined by the type, 
the cumulative dose and the treatment duration [55]. Despite all cytotoxic drugs 
have a negative impact on the ovary, alkylating agents such as cyclophosphamide, 
busulfan and dacarbazine, are associated with the highest risk of infertility, with 
an effect that increases proportionally with increasing doses [56]. The individual 
gonadotoxic potential of chemotherapeutic drugs has been established for the most 
commonly used ones [57, 58] (Table 2).
Table 2. Risk of ovarian insufficiency for common chemotherapeutic drugs. Adapted 
with permission from [57, 58].
High (> 80%) Intermediate Low (< 20%) Very low/no risk
Cyclophosphamide Cisplatin Bleomycin Vincristine








However, as chemotherapeutic regimens usually combine multiple drugs, the 
gonadotoxicity of every individual agent is difficult to ascertain. Therefore, a 
better risk assessment for infertility in clinical settings has been predicted tak-
ing into account the type of malignant disease and the associated treatments [58] 
(Table 3). For example, conditioning regimens used before hematopoietic stem 
cell transplantation (HSCT) and total body irradiation (TBI) carry the highest 
risk of ovarian insufficiency, together with treatment of metastatic sarcomas [58]. 
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Table 3. Risk of ovarian insufficiency based on treatment protocols for common 
 cancers in childhood and adolescence. Adapted with permission from [58].
High (> 80%) Intermediate Low (< 20%)








Hodgkin’s disease: treatment 
with alkylating-drugs






Metastatic Ewing’s sarcoma Stage II-III soft-tissue 
sarcoma
Brain tumor: surgery only, 
 cranial irradiation < 24 Gy
Neuroblastoma Germ-cell tumor 
(no radiotherapy)
Non-Hodgkin lymphoma  
Hodgkin’s disease: 




 irradiation > 24 Gy
A variety of malignant and non-malignant conditions require treatment protocols 
that expose the patients to a high risk of infertility. The most frequent malignant 
diseases in children include hematologic cancers, such as Hodgkin’s lymphoma, 
non-Hodgkin’s lymphoma, and leukemia, together with central nervous system 
(CNS) tumors [59]. Depending on the disease stage and evolution, these patients 
can become eligible for HSCT (allogenic or autologous) and thus be exposed to 
a high risk of infertility. Non-malignant systemic conditions, such as primary 
immunodeficiency, sickle cells anemia, thalassemia, aplastic anemia and other 
inherited bone marrow failure syndromes are also candidates to allogenic HSCT 
and constitute an increasingly prevalent indication for OTC in pediatric patients, 
as a consequence of the improvement of diagnostic tools and earlier referral. 
1.3.2.1 Mechanisms involved in chemotherapy-induced PF loss
Exposure to chemotherapeutic drugs induces depletion of the ovarian follicles 
(both PFs and growing follicles) and ovarian atrophy [60-63]. The mechanisms 
by which cytotoxic drugs deplete PFs are not yet fully understood but during the 
last  decade some of the pathways involved have been clarified. The two main 
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researched mechanisms are follicle apoptosis and PF activation followed by 
 depletion, the latter known as the ‘burn-out’ theory:
i) Follicle apoptosis is triggered by DNA damage following exposure to cytotoxic 
drugs. Dividing cells are particularly sensitive, as shown by apoptotic markers’ 
positivity in granulosa cells of exposed growing follicles [63]. In the mature 
oocyte, that is a non-dividing cell, apoptosis is mediated by several molecules 
including B-cell lymphoma 2 protein (BCL2) associated X protein (BAX) and 
caspases [64]. Alkylating agents have been shown to cause DNA damage even 
in non-dividing cells, thereby affecting also dormant PFs. In recent years, some 
of the pathways responsible for PF apoptosis have been unraveled. A homolog 
of the anti-oncogene P53, and specifically the p63 isoform TAp63, has been 
shown to mediate DNA damage and apoptosis of PF oocytes following DNA 
injury [65].
ii) The ‘burn-out’ theory suggests that chemotherapy agents trigger the activation 
of dormant PFs, which is followed by their massive depletion [66]. Alteration 
of pathways controlling PF dormancy/activation has been shown after exposure 
to chemotherapeutic agents: cyclophosphamide can upregulate PI3K/PTEN/
AKT signaling pathway thereby causing activation and growth of PFs followed 
by their depletion [66] (Figure 5). Furthermore, in physiological conditions, 
growing follicles secrete AMH that contributes to the maintenance of PFs’ 
dormancy [29]. The destruction of growing follicles caused by chemotherapy 
provokes a reduction of AMH secretion and a loss of its suppressive action on 
the activation of PFs [67].
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Figure 5. Regulation of primordial follicle activation in physiological conditions (A) 
and its dysregulation following exposure to cyclophosphamide (Cy) (B). Adapted with 
 permission from [66].
1.3.3 Radiotherapy
Whole-body, abdominal, or pelvic irradiation cause damage to the ovary and to 
the uterus [68]. Oocytes are very sensitive to radiation and both PFs and growing 
follicles can be affected by radiotherapy (RT). As for chemotherapy, the extent 
of damage depends on the dose, the fractionation schedule and the age at treat-
ment. The median lethal dose (the dose needed to destroy 50% of the PFs present 
in the ovary) is estimated to be less than 2 Gy [69] and a dose greater than 5 Gy 
is sufficient to cause ovarian insufficiency, regardless of the age [70]. This is 
meaningful considering that doses of TBI administered before HSCT range from 
2 to 16 Gy. Fractionated doses are more tolerable than high single doses, even 
though the repetitive nature of fractionated RT might interfere with cell repair 
[58]. Regarding the age at treatment, older patients have a lower quantity of PFs 
and are therefore less tolerant to the ovarian insult than younger patients. This 
has been clearly demon strated by Wallace et al. who have shown that, as the age 
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at treatment increases, a progressively lower dose of RT is required  to induce 
POI in the 97.5% of the patients. The sterilizing dose of RT is estimated to be 
20.3 Gy for a newborn child and 14.3 Gy for a 30-year-old woman [58]. Cranial 
or craniospinal irradiation, frequently used in the treatment of CNS tumors and 
in acute lymphoblastic leukemias, can disrupt the hypothalamic-pituitary-gonadal 
axis and cause a central hypogonadism, especially for doses > 30 Gy [58]. As a 
result of the above described mechanisms, it is understandable that the combina-
tion of TBI and alkylating agents, used in conditioning regimens preceding HSCT, 
bears the highest risk, leaving almost 100% of patients infertile. Previous research 
conducted by Vatanen et al. showed that only 25% of girls conditioned with TBI 
for HSCT had a residual ovarian function at long-term follow-up [71]. 
1.3.4 Options for fertility preservation 
1.3.4.1 Embryo cryopreservation and oocyte cryopreservation
Embryo cryopreservation and oocyte cryopreservation are established techniques 
for preservation of fertility in adult women. Embryo cryopreservation requires 
a stable relationship and both procedures are performed by controlled ovarian 
stimulation and transvaginal oocyte retrieval. Therefore, the patient should be 
post-pubertal and it should be possible to postpone the start of chemotherapy of 
at least 10-12 days [72]. 
1.3.4.2 Ovarian tissue cryopreservation (OTC)
When the patient is prepubertal or when chemotherapy start cannot be delayed, 
cryopreservation of the ovarian tissue is the only option to preserve fertility [58, 
72, 73]. Over the last 15 years, OTC has become an established technique in many 
countries but it is still considered experimental for prepubertal girls and is often 
performed in the context of a research protocol (Figure 6). 
Wallace et al. developed [58] and validated [74] selection criteria for OTC that 
are nowadays applied in many centers across Europe:
• Age younger than 35 years
• No previous chemotherapy or radiotherapy if aged 15 years or older at  diagnosis, 
but mild, non-gonadotoxic chemotherapy acceptable if younger than 15 years
• A realistic chance of surviving for 5 years
• A high risk of premature ovarian insufficiency (>50%)
• Informed consent (from parents and, where possible, patient)
• Negative serology results for HIV, syphilis, and hepatitis B
• Not pregnant and no existing children
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Figure 6. Options for fertility preservation in prepubertal patients and patients that require 
immediate chemotherapy (A) and in postpubertal patients or patients that can delay the start 
of chemotherapy (B). Reproduced with permission from [72], Copyright Massachusetts 
Medical Society.
However, selection criteria are not completely homogeneous among different 
centers, especially regarding the definition of high risk of infertility, the upper 
age limit and the previous exposure to chemotherapy. In Nordic countries, recom-
mendations on fertility preservation for girls and young women with childhood 
cancer have been established by the Nordic Society for Pediatric Hematology and 
Oncology (NOPHO) in 2013:
i) All girls should be examined regarding pubertal development (Tanner stage 
and menstrual history) at diagnosis and should be informed of the risk for 
impaired fertility following the planned treatment
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ii) If there is a very high risk of infertility, the patient and her parents should be 
informed of possibilities for fertility preservation by a professional, specially 
assigned for this purpose, e.g. a pediatric endocrinologist, a gynecologist or 
fertility specialist, according to local availability and routines. It is important 
that the autonomy of the girl is respected and that she, if mature enough, is 
offered the opportunity of individual consultation.
iii) After treatment, all girls who have received alkylating agents or abdominal 
irradiation should after sexual maturation be offered referral to a gynecologist 
or fertility specialist for evaluation, counseling and for considering the 
possibility for ovarian hyperstimulation and cryopreservation of oocytes.
iv) If the girl is menstruating, mature enough to give informed consent, is facing 
cancer therapy with very high risk of infertility AND therapy can be delayed 
1-2 weeks, ovarian hyperstimulation and cryopreservation of oocytes may 
be considered. The responsible oncologist must be consulted to make sure 
that no contraindications, such as bleeding disorders or too long delay of 
cancer therapy, to such procedures are present. At present, cryopreservation 
of non-fertilized oocytes is routine among older women. The girl should get 
information adjusted to her age.
v) All girls regardless of maturational stage who are facing or receiving oncologi-
cal treatments associated with a very high risk of infertility, could be offered 
the experimental procedure of ovarian cortical tissue cryopreservation. 
vi) In menstruating girls, cryopreservation of ovarian tissue can precede controlled 
ovarian hyperstimulation (see above). The responsible oncologist must be 
consulted to make sure that no contraindications to such procedures are present.
vii) Adaptation to adult guidelines should be considered when the girl has reached 
the maturity of a young adult.
viii) Patients eligible for cryopreservation of ovarian cortical tissue are those 
undergoing allogeneic/autologous HSCT, radiotherapy with ovary in the 
field, ovariectomy due to any cause.
At diagnosis, patients should be informed about their risk of infertility and those 
with a high risk should be offered fertility preservation [6]. Ovarian cortex stripes 
are isolated from cortical biopsies or from the whole ovary after oophorectomy 
and cryopreserved by slow-freezing method. The procedure is, when possible, 
combined with other surgical procedures under general anesthesia, such as posi-
tioning of a central venous catheter (CVC) or surgery for removal of tumor mass. 
Once the patient has been cured and a wish for childbearing arises, reimplantation 
of the ovarian tissue can be performed. The most common sites of reimplanta-
tion are peritoneal pockets inside the pelvic cavity or the ovarian medulla of the 
 remaining ovary [75]. Starting from 2004, more than 130 live births have been 
reported worldwide following reimplantation of ovarian tissue stored from adult 
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women, showing that cryopreserved ovarian tissue is able to restore ovarian func-
tion in more than 95% of cases [72, 76]. 
However, there are still many uncertainties, especially for application in pediatric 
patients. First, knowledge of how patients respond to reimplanted tissue collected 
prior to puberty is limited. Some recent reports provide the proof of principle that 
this technique may work also in such cases. Ovarian tissue cryopreserved from 
two pre-pubertal patients restored puberty when reimplanted back [77, 78] and 
two successful pregnancies have been reported after reimplantation of ovarian tis-
sue harvested at 9 and 13 years of age [79, 80]. With increasing time from OTC 
establishment in many centers, more reports are expected in the coming years. 
A debated issue regards whether OTC should be performed before or after the 
patient has been exposed to chemotherapy and which extent of exposure is 
acceptable. Ideally, OTC should be performed before initiation of chemotherapy, 
to avoid damage to the follicles and guarantee the best quality of the harvested 
ovarian tissue [74, 81-83]. However, this is only possible when the patient falls 
in a definite risk category for infertility already at the time of diagnosis. In many 
cases, the prognosis is uncertain or the course of the disease increases the risk 
category time after the initial diagnosis. In this case, fertility preservation becomes 
an option only after the first cycles of treatment have been performed [74]. First-
line cancer treatments are considered to have a small effect on follicles, but this 
assumption has been recently questioned. A deterioration of the follicular intra-
cellular quality, such as increase in abnormal granulosa cell nuclei and oocyte 
vacuolization, was evidenced in the ovaries of patients exposed to chemotherapy 
(both with and without alkylating agents) before OTC compared to non-exposed 
ones [81]. Another study explored cryopreservation of in-vitro matured oocytes 
as an additional technique to ovarian tissue cryopreservation in pediatric patients 
exposed and not exposed to chemotherapy before OTC and concluded that expo-
sure to chemotherapy significantly reduced the number of collected oocytes and 
the amount of in-vitro matured oocytes [84]. El Issaoui et al. reported a significant 
reduction of the ovarian volume in a cohort of girls below 18 years who were 
exposed to first-line chemotherapy before OTC, compared to those that were not 
exposed to any chemotherapy, to an extent that was directly proportional to age 
[82]. Finally, previous exposure to chemotherapy significantly reduced the survival 
and development of follicles in culture, and increasing doses of alkylating agents 
were identified as major predictor of follicle atresia [83]. Despite evidence of an 
effect of first-line chemotherapy on the quality of ovarian follicles, reimplantation 
of harvested ovarian tissues after exposure to chemotherapy is equally effective 
in terms of restoration of the ovarian function, at least in adult patients [85-87].
Another major concern is that reimplantation of ovarian tissue involves the risk of 
seeding malignant cells back to the patient, in case the ovary had been contaminated 
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at the time of active disease [88-93]. This is particularly true for certain types of 
malignancies, such as leukemia and neuroblastoma, which are highly prevalent 
categories of tumors among children [90, 94, 95]. For this reason, in most clinical 
settings, only patients with cancers associated with a low risk of ovarian metastasis 
are currently considered for reimplantation [94, 95]. For leukemias, if the patient 
is in complete remission at the time of OTC, the risk of ovarian contamination is 
very low [91]. However, the bone marrow minimal residual disease (MRD) does 
not always corresponds to the ovarian MRD and a significant contamination has 
been found in ovarian tissues of patients suffering from leukemia even at the 
time of bone marrow remission [96]. Despite these uncertainties, reimplantation 
of ovarian tissue from patients affected by leukemia has been performed in a few 
cases, where the tissue was harvested during full remission and after extensive 
tissue evaluation to exclude ovarian contamination [85, 87, 97, 98]. It is impor-
tant to stress that tissue evaluation cannot be performed in the same fragment of 
tissue that will be used for reimplantation, because the tissue will not survive the 
procedure. Moreover, detection of ovarian MDR by real-time quantitative poly-
merase chain reaction (RT-qPCR) is the most sensitive way to detect malignant 
contamination but can only be applied when a disease-specific molecular marker 
is identified [94, 99]. 
Alternative strategies to overcome the risk of reseeding the disease in these 
patients are under investigations and include transplantable artificial ovary and 
in vitro development of primordial follicles. A protocol for the isolation of pri-
mordial follicles to obtain a disease-free  follicle suspension has been developed 
recently [100] and development of PFs up to the antral stage has been reported 
after transplantation and xenografting in mice [101-103]. Restoration of fertility 
in ovariectomized mice has been shown using a 3D-printed ovary seeded with 
follicles [104]. A multistep culture system has been developed by McLaughlin 
et al. and was shown to support follicle maturation from primordial to metaphase 
II stage in vitro [105]. However, the efficiency is low and several issues remain 
to be solved. Suboptimal culture conditions, cryogenic cell damage and chemo-
therapeutic agents to which patients have been exposed before harvesting the 
tissue may have an impact on the oocyte viability and maturing potential in vitro 
and the effects of the artificially-induced maturation on the genomic stability of 
the oocytes need to be assessed [76]. 
1.3.5 Follow-up programs for cancer survivors and assessment 
of ovarian reserve
Ovarian and/or hypothalamic-pituitary damage following cancer treatments can 
result in hypergonadotropic or hypogonadotropic hypogonadism respectively. In 
prepubertal patients hypogonadism translates clinically into failure of pubertal onset, 
whereas in patients that already started puberty hypogonadism will manifest as 
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lack of pubertal progression, primary or secondary amenorrhea. Recommendations 
for premature ovarian insufficiency surveillance for childhood, adolescent and 
young cancer survivors have been proposed by the International Late Effects 
of Childhood Cancer Guideline Harmonization Group in collaboration with the 
European Union-founded PanCareSurFup consortium and published in 2016 [50]. 
Monitoring of growth and puberty by Tanner stage is recommended annually or 
as clinically indicated for prepubertal girls treated with potentially gonadotoxic 
treatments. Girls with no signs of puberty by age 13, failure in pubertal progres-
sion, primary amenorrhea by age 16 or menstrual cycle dysfunction should be 
referred to pediatric endocrinology or gynecology. FSH and estradiol should be 
tested in prepubertal girls treated with potentially gonadotoxic treatments who 
fail to initiate or progress through puberty, starting from 11 years of age. AMH 
measurement for assessment of the ovarian reserve is only recommended after 
25 years of age in conjunction with FSH and estradiol [50]. In pediatric patients, 
AMH levels decline already at cancer diagnosis [106] and soon after treatment, 
showing a recovery timing that is inversely correlated with the intensity of the 
gonadotoxic treatment [107]. However, its utility as marker of ovarian reserve 
in prepubertal girls is still uncertain and requires further research [108]. Antral 
 follicle count (AFC) by vaginal ultrasound is the most reliable way for prediction 
of the ovarian reserve, but is not indicated in young patients [109]. No consensus 
guidelines exist for the pubertal induction and maintenance with hormone replace-
ment therapy (HRT) in this specific population, therefore guidelines for Turner 
syndrome are usually applied [59, 110, 111]. 
1.4 Future perspectives
Future research efforts should focus on the elucidation of these areas of uncertainty. 
In particular, the potential of prepubertal ovarian tissue to restore fertility after 
reimplantation, the consequences of chemotherapy exposure before OTC on the 
fertility-restoring potential and quality of the ovarian tissue and the effectiveness 
of alternative strategies such as the artificial ovary or PF maturation in vitro for 
patients with diseases at high risk of ovarian contamination are major areas of 
interest. Moreover, the establishment of harmonized selection criteria for fertility 
preservation is an important issue that would allow to target the patients that will 
benefit the most from the procedure and optimize the risk-benefit ratio. Further 
understanding of genetic variations responsible for different individual suscepti-
bility to ovarian gonadotoxic insults as well as investigation of the gonadotoxic 





The overall objectives of this thesis are:
• to define the impact of IUGR on the ovary using a rat model of placental 
insufficiency
• to define the impact of first-line chemotherapy on the ovary using ovarian 
tissues harvested from cancer patients for fertility preservation 
• to assess the efficacy of fertility preservation criteria in selecting patients at 
high risk of infertility 
• to analyze the implementation of the OTC service in a large pediatric oncology 
unit
2.2 Specific aims 
The specific objectives of this thesis are:
• to study the effects of IUGR on ovarian follicles and gene expression in ovaries 
of rats from neonatal to peripubertal ages
• to study the effects of exposure to first-line chemotherapy on pre-antral 
follicles and ovarian stroma in a cohort of girls and young women with onco-
hematological diseases
• to study the clinical outcomes of a cohort of patients who underwent OTC, in 
terms of ovarian function (pubertal development, hormonal profiles and need 
for estrogen replacement therapy) and put them in relation to age, diagnosis 
and treatment in order to verify if the selection criteria for OTC target the right 
patients
• to study the fruition rate of the OTC service and analyze the timing of OTC, 
i.e. the time from indication to execution of the procedure, in relation to the 
exposure to chemotherapy 
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3 MATERIAL AND METHODS
3.1 Ethics
3.1.1 Paper I
The experimental animal model was approved by the Committee for Animal 
Research of Tor Vergata University in Rome, Italy and was performed according 
to the Guide for the Care and Use of Laboratory Animals of the National Institutes 
of Health (NIH Publication No. 85–23, revised 1996). All the procedures complied 
with the Italian regulations for laboratory animal care.
3.1.2 Paper II
Ovarian tissues were donated by patients who underwent OTC at the Helsinki 
University Central Hospital (Finland), the Tampere University Hospital (Finland) 
and the Oslo University Hospital (Norway). For pediatric patients (referred to 
Helsinki University Central Hospital), OTC was performed in the context of a 
research project approved by the Ethics Committee of Helsinki University Central 
Hospital (Dnr 340/13/03/03/2015). Written informed consents for pediatric patients 
were given by their guardians and by the patients when appropriate. Adult patients 
(referred to Tampere and Oslo University Hospitals) were offered OTC as part 
of a fertility preservation program. Written informed consent for the quality con-
trol of ovarian tissue, including morphological analysis and in vitro culture, was 
signed by all patients. The need of further ethical licenses were discussed with the 
Oslo University Hospital, the Finnish National Supervisory Authority for Welfare 
and Health and the Finnish Medicines Agency. In accordance with the Medial 
Research Act (488/1999) and Act on the Medical Use of Human Organs, Tissues 
and Cells (101/2001), written informed consent for the use of ovarian tissues for 
research purposes was sufficient and no further ethical permits were required. All 
the patients’ data handled in Sweden were anonymized. 
3.1.3 Paper III
The collection of register data of patients with indication for OTC was approved 
by the Helsinki University Central Hospital (Hospital license nr HUS 248/2019). 
Data handled in Sweden were anonymized. OTC was offered as part of a research 
protocol approved by the Ethics Committee of Helsinki University Central Hospital 
(Dnr 340/13/03/03/2015). For patients who underwent OTC, the parents and the 
patients, when appropriate, gave their written informed consent to the OTC pro-
cedure and the related research. 
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3.2 Animals
IUGR was induced by bilateral ligature of the uterine arteries on day 19 of ges-
tation in time-dated Sprague-Dawley pregnant rats (Charles River Laboratories 
Inc., Italy) [112]. Control animals were obtained from pregnant rats undergoing a 
‘sham’ procedure, in order to equalize the effects of anesthesia and surgical stress. 
After spontaneous delivery (day 22-23 of gestation) IUGR animals were selected 
at birth according to a body weight (BW) of less than 2 standard deviations (SDs) 
compared to the mean BW of the control litter. Newborn pups were assigned to 
feeding dams with a maximum number of six per litter to equalize postnatal nutri-
tion. At 21 days post-partum (dpp), pups were weaned onto standard rat chow diet 
(Mucedola S.R.L., Milano, Italy) and placed in groups of three to five, with the 
males and females separated. The animals were sacrificed by cervical disloca-
tion at postnatal days 5, 20 and 40 dpp, representing the neonatal, juvenile and 
peripubertal periods, respectively. Body weight and ovary weight were measured 
weekly and at sacrifice, respectively. Each group of IUGR and shams at 20 and 
40 dpp included six animals from at least three different litters to ensure  biological 
variability. For the 5 dpp old animals, 8 IUGR and 4 sham animals from three dif-
ferent litters were included. Gene expression analysis was performed in 6 IUGR 
and 3 sham animals and histological evaluation was performed in 4 IUGR and 
4 sham animals.
3.3 Tissue processing (Paper I)
Ovaries excised from euthanized animals were processed as follows. For histologi-
cal analysis, one gonad was fixed in 4% paraformaldehyde (PFA) (P/N15812–7, 
Sigma-Aldrich, MO, USA) overnight at 4 °C, dehydrated in ethanol at increasing 
concentrations followed by butyl acetate (P/N 45860, Sigma-Aldrich, MO, USA), 
and embedded in paraffin (Paraplast X-TRA®; P/N P3808, Sigma-Aldrich) at 
61	°C	overnight.	Ovaries	were	cut	serially	to	a	thickness	of	5	μm,	mounted	on	
microscope slides (P/N10143352, Superfrost Plus, Thermo Scientific, MA, USA) 
and placed at 37 °C overnight. 
3.4 Immunohistochemistry (Paper I)
For immunohistochemical (IHC) analysis, three sections per ovary were stained 
and evaluated. Chosen sections corresponded to approximatively the 25, 50 and 
75% of the entire tissue block. Tissue sections were dewaxed in xylene (P/N 02080, 
HistoLab, Gothenburg, Sweden) for 10 minutes and then rehydrated in ethanol at 
decreasing concentrations. Antigen retrieval was performed using citrate buffer 
at pH 6.0 at 95 °C for 10 minutes. Slides were incubated first in methanol + 3% 
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H2O2 for 10 minutes at room temperature for endogenous peroxidase blocking, 
and then in tris-buffered saline (TBS) + 2% horse serum for 30 minutes at room 
temperature to prevent nonspecific antibody binding. Samples were then incubated 
overnight at 4 °C with primary antibody against AMH (P/N MCA2246, Bio-Rad, 
CA, USA) or unspecific IgGs (for negative control) dissolved in TBS + 2% horse 
serum. After washing with TBS + 0.01% Tween20 (P/N P1379, Sigma Aldrich,), 
slides were incubated with biotinylated secondary antibody (P/N BA1400, Vector 
laboratories, CA, USA), and then with avidin-biotin-peroxidase complex pre-
pared using Vectastain ABC kit (P/N PK-6100, Vector Laboratories, CA, USA) 
for 30 minutes each at 37 °C. After washing, slides were stained with DAB (P/N 
SK-4105, Vector Laboratories) and then with hematoxylin solution modified 
according to Gill III, followed by tap water rinsing for 5 minutes. Finally, slides 
were dehydrated with ethanol at increasing concentrations, cleared with xylene 
and mounted with Pertex (Cell Path, Hemel Hempstead, UK) and cover slips. 
3.5 Histological analysis (Paper I)
For histological evaluations, rat ovarian sections were stained with hematoxylin 
and eosin. In brief, after dewaxing in xylene and rehydration in ethanol, samples 
were incubated for 3 minutes with hematoxylin solution modified according to 
Gill III, rinsed with tap water for 20 minutes, and soaked in 70 and 95% ethanol 
for 5 minutes each. Slides were then incubated with eosin for 30 seconds, dehy-
drated with 100% ethanol and xylene and finally mounted with Pertex (Cell Path, 
Hemel Hempstead, UK) and cover slips. Three sections per ovary, corresponding 
to approximatively the 25, 50 and 75% of the entire tissue block, were selected 
for follicle quantification. For each section, only follicles with a visible nucleus 
were counted and classified as follows: (1) PFs, oocyte surrounded by a single 
layer of flattened pre-GCs; (2) primary follicles, oocyte surrounded by two or more 
cuboidal GCs up to one complete layer of cuboidal GCs; (3) secondary follicles, 
oocyte surrounded by at least two layers of GCs but no antrum; and (4) tertiary 
follicles, follicles with a visible antrum. The follicle numbers were reported as 
follicular density (calculated as number of follicles /mm3 of ovarian tissue). Two 
blinded observers evaluated the same sections independently and the results were 
compared showing an inter-observer concordance above the 90%. As indirect 
measure of the ovulation rate, corpora lutea (CL) were quantified in the same 
three sections per animal. Total ovarian volume (mm3) was calculated using the 
ellipsoid	formula	4/3	*	π	*	a	*	b2,	where	‘a’	corresponds	to	the	length	of	the	ovary	
(a = total number of sections (n) multiplied by 0.005 (representing the thickness 
of	each	section)),	and	‘π	b2’	is	the	area	of	the	middle	section	(Am)	of	the	ovary.	
Therefore, total ovarian volume (V) = 4/3 * Am * n * 0.005. 
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3.6 RNA isolation and cDNA synthesis
Total RNA was extracted from entire frozen ovaries using an RNeasy Mini Kit 
(P/N 74104, Qiagen, Veno, Netherlands). Samples were dissolved in Qiagen lysis 
buffer and then homogenized twice for 30 seconds in an ULTRA-TURRAX T25 
homogenizer (JANKE and KUNKEL, Staufen, Germany). The supernatant was 
mixed with half of its volume amount of 70% ethanol, the mixture was transferred 
to RNeasy spin columns and processed according to the manufacturer’s protocol. 
The extracted RNA was stored	at	−	80	°C	after	quantification	of	RNA	concentra-
tions with a single-beam UV/vis spectrophotometer (P/N 6132000032, Eppendorf, 
Hamburg, Germany). To generate cDNA, the IScript™ cDNA synthesis kit (P/N 
170–8891, Bio-Rad, CA, USA) was used according to the manufacturer’s protocol. 
One	μg	of	RNA	was	reverse-transcribed	on	a	thermocycler	(P/N 4359659, Applied 
Biosystems, MA, USA) using random hexamers	in	a	total	reaction	volume	of	20	μl.	
3.7 Taqman low-density arrays (TLDAs) 
Comparative analysis of gene expression of IUGR and control animals was 
performed by TLDA cards (P/N 4342259, ABI, Hilden, Germany) and TaqMan 
Gene expression Master Mix (P/N 4369510, Applied Biosystems, MA, USA), 
according to the manufacturer’s protocol. The TLDA cards were pre-loaded with 
96 TaqMan gene expression assays of importance for germ cell and gonadal 
somatic cell function and differentiation, cell proliferation, apoptosis and metabo-
lism, and six endogenous controls assigned for normalization. Gene expression 
was normalized to the mean of five out of six endogenous controls (Actin beta, 
Beta-2-microglobulin, Catenin beta 1, Eukaryotic translation elongation factor 
1 alpha 1 and Glyceraldehyde-3-phosphate dehydrogenase) of the same sample 
(dCt), selected according to their stability. Data from one randomly chosen animal 
were used as a calibrator (ddCT) and data from all other animals were normalized 
to it. Gene expression was finally presented as relative expression, using the fold 
change	(2	−	ddCT) method for calculation.
3.8 Serum amh measurement
Serum levels of AMH were measured by Gen II ELISA Reagent kit REF A79765 
and Calibrator kit A79766 (Beckman Coulter) according to the manufacturer’s pro-
tocol. The detection limit was 0.08 ng/mL and the intra and inter-assay  coefficients 
of variation were 4.3 and 9.8%, and 1.4 and 4.3%, for the low and high levels of 
the standard curve, respectively.
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3.9 Tissue processing (Paper II)
Ovarian cortical tissue was collected from 43 patients. For immunohistochemical 
analysis, ovarian tissues were freshly fixed in PFA (27 patients). For histological 
analysis, cryopreserved ovarian tissues were thawed and fixed in Bouin’s solu-
tion (27 patients). Eleven patients had ovarian tissue fixed both in PFA and Bouin, 
whereas in the other cases one patient had the ovarian tissue fixed either in PFA 
or in Bouin.
3.10 Immunohistochemistry (Paper II)
Immunohistochemical analyses were performed using PFA-fixed samples. FOXO3A 
analysis was performed in one section/patient in 8 patients (3 treated and 5 untreated) 
and	H2A	histone	family	member	X	phosphorylated	on	serine	139	(γH2AX)	analysis	
in one section/patient in 18 patients (8 untreated and 10 treated). After dewaxing 
and rehydration of the slides, antigen retrieval was performed with citrate buffer 
+ 0.05% Tween20, pH 6.0 at 95 °C for 45 minutes. Slides were then blocked in 
5% BSA and normal donkey serum (S30, EMD Millipore, Darmstadt, Germany) 
and then incubated with polyclonal rabbit FOXO3A antibody (PA5-27145, Thermo 
Fisher	Scientific,	MA,	USA),	polyclonal	rabbit	γH2AX	antibody	(ab2893,	Abcam,	
Cambridge, UK) or polyclonal rabbit IgG antibody (ABIN376827, antibodies-
online, Aachen, Germany) for negative control overnight at 4 °C. Donkey anti-rabbit 
Alexa Fluor 555 conjugated antibody (A31572, Life Tech, MA, USA) diluted in 
5% BSA and normal donkey serum (S30, EMD Millipore, Darmstadt, Germany) 
was used for detection of the primary antibodies (1 hour at room temperature). 
Sections were mounted using VECTASHIELD mounting medium with DAPI 
(H-1200, Vector Labs, CA, USA). 
3.11 Histological analysis (Paper II)
A subset of 10 sections was evaluated by two blinded observers independently, 
showing an inter-observer concordance above the 90%. Subsequently, each observer 
evaluated half of the study material. Bouin’s fixed sections stained with hema-
toxylin–eosin were digitalized using a spectral scanner (Vectra 3 system, Perkin 
Elmer, MA, USA) and every fifth section was evaluated using Pannoramic Viewer 
software (3DHistech, Budapest, Hungary). Follicles with a visible oocyte nucleus 
were counted and classified according to established morphological criteria [9], as 
follows: (1) primordial follicles, oocyte surrounded by a single layer of flattened 
granulosa cells; (2) intermediary follicles, oocyte surrounded by a single layer of 
flattened and at least two cuboidal granulosa cells; (3) primary follicles, oocyte 
surrounded by one complete layer of cuboidal granulosa cells; and (4) secondary 
follicles, oocyte surrounded by more than one layer of cuboidal granulosa cells. 
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A follicle was considered intact and healthy if the round shape was preserved, the 
oocyte nucleus was central, round and not pyknotic, there was no contraction or 
eosinophilia of the cytoplasm, and there was full contact between the oocyte and 
the surrounding granulosa cells. On the opposite, follicles were classified as atretic 
follicles if they had a distorted follicle shape, non-circular or pyknotic oocyte 
nucleus, eosinophilic cytoplasm or dislocated/detached GCs. Follicle diameter 
and oocyte nucleus diameter were calculated for each follicle as the arithmetic 
mean of two perpendicular measurements. 
Detection of fibrotic areas in the ovarian stroma was performed in one section/
patient in 12 patients (6 untreated and 6 treated patients) using Bouin’s fixed tissues. 
The trichrome stain kit (ab150686, Abcam, Cambridge, UK) was used accord-
ing to the manufacturer’s instructions, as follows: tissue sections were incubated 
in Weigert’s iron hematoxylin for 5 minutes, followed by Biebrich scarlet-acid 
 fuchsin solution (15 minutes), phosphomolybdic/phosphotungstic acid solution (10 
minutes), aniline blue solution (5 minutes) and acetic acid solution (3 minutes). 
Slides were then dehydrated in increasing ethanol concentration, cleared with 
xylene and mounted with Pertex® (Histolab, Askim, Sweden). 
For stromal cell death detection, TUNEL staining assay (11684795910, Roche, 
Penzberg, Germany) was performed in one section/patient in 13 patients (6 untreated 
and 7 treated) using PFA-fixed samples. De-paraffinized and rehydrated tissue 
sections were incubated with proteinase K followed by TUNEL reaction mixture 
for 1 hour at 37 °C. Positive controls were treated with DNase I for 20 minutes at 
room temperature before TUNEL reaction. For negative controls incubation without 
detection enzyme was performed. Samples were mounted using VECTASHIELD 
mounting medium with DAPI (H-1200, Vector Labs, CA, USA). 
3.12 Steroid production in culture
Steroid hormones were measured in used culture media where thawed ovarian 
tissue pieces were cultured for 7 days in a previous study from our group [83]. 
Cortisol,	corticosterone,	estradiol,	androstenedione,	17α-OH	progesterone,	pro-
gesterone, dehydroepiandrosterone, dihydrotestosterone, and testosterone were 
quantified in media samples from 27 patients on days 4 and 7 of culture using 
ultra-performance liquid chromatography tandem mass spectrometry [113]. Nine 
blank media samples were used as controls.
3.13 Study population (Paper III)
Data were collected from a total of 206 patients who were eligible for OTC between 
2002 and 2019 and were referred to the Helsinki University Central Hospital 
(Finland) from different centers, including municipality hospitals belonging to the 
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Helsinki University Hospital. For patients with allogenic HSCT, referral centers 
were all five University hospitals in Finland. The OTC procedure was offered to 
patients at very high risk of POI (i.e. HSCT or radiotherapy with ovary in the field). 
In 90 of the 206 patients OTC was successfully performed, when possible at the 
same time of another operation under general anesthesia (central venous catheter 
positioning or removal of tumor mass). Different proportions of the ovary were 
harvested, from a minimum of the 25% of the ovary to the entire organ. Fourteen 
patients underwent unilateral oophorectomy based on the predicted risk of irre-
versible damage due to ovarian irradiation. The slow-freezing method was used to 
cryopreserve the ovarian tissue pieces [114]. Two-thirds of the tissue were stored 
in biobank facilities at the Helsinki University Central Hospital for the patients’ 
future use. The remaining third was anonymized and cryopreserved for quality 
control of ovarian tissue, including morphological analysis and in vitro culture. 
For the 90 patients who underwent OTC, age and pubertal status at OTC, diagno-
sis, indication for OTC, time from OTC indication to OTC execution, treatment 
characteristics and survival time were obtained from the hospital records. For the 
other 116 patients, who had indication to OTC but did not undergo the procedure, 
age and pubertal status at treatment, diagnosis, treatment characteristics and sur-
vival time were retrieved from the hospital records. 
Of the 90 girls who underwent OTC, 65 became long-term survivors and were 
followed-up at the outpatient clinic. Follow-up included pubertal evaluation, 
menstrual history and laboratory examinations and was performed initially every 
six months and later annually. Occurrence of spontaneous puberty and menarche, 
need of hormone replacement therapy (HRT), measurements of FSH, LH, AMH 
and estradiol (E2) were collected retrospectively. Prepubertal hormonal levels 
and those measured during HRT were excluded from the analysis. POI requiring 
estrogen substitution was defined as follows: absence of spontaneous puberty and 
FSH levels > 25 IU/l after gonadotoxic cancer treatment in girls that were pre-
pubertal at the time of treatment; lack of pubertal progression, primary or second-
ary amenorrhea and FSH levels > 25 IU/l in girls that had already entered puberty 
or started menarche at the time of treatment. 
Indication for OTC was subclassified as follows: HSCT or abdominal irradiation 
for (1) correction of severe hematological or immunological disease (i.e. bone 
marrow failure syndromes, immunodeficiencies, myelodysplastic syndromes), 
(2) metastatic cancer, (3) high risk treatment protocol according to stratifying 
factors at diagnosis (high leucocyte count, genetic subtypes or tumor histology), 
(4) poor response to induction therapy, (5) relapse, (6) second tumor. A last cat-
egory of patients, referred in the rest of the thesis as ‘patient’s decision’, included 
3 patients that expressed their will to have OTC performed because of planned 
treatment with high-dose alkylating agents that put them at high risk of POI, even 
though they did not meet the strict criteria for OTC (HSCT or radiotherapy with 
ovary in the field).
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Cyclophosphamide equivalent doses (CED) were calculated as described by Green 
et al. [115]. Isotoxic dose equivalents (DIE) for anthracycline equivalent doses were 
calculated using a conversion factor of 1 for doxorubicin, 0.833 for  daunorubicin, 
5.0 for idarubicin and 4.0 for mitoxantrone [116]. Exact gonadal irradiation dose 
was available for all cases exposed to whole abdomen irradiation and TBI. Gonadal 
irradiation was estimated as equal to the 50% of the local irradiation dose for cases 
who had RT to the retroperitoneum, kidney, spine or tumor area. In one case the 
exact dose to the ovaries was available from dosimetry. 
3.14 Statistical analysis 
3.14.1 Paper I
Analyses were performed using the SigmaStat (v 11.00) package (SPSS, Inc., IL, 
USA). The continuous variables among groups were compared using Student’s 
T-test, based on Shapiro-Wilk normality test. Results are shown as mean ± SD. 
Differences were considered statistically significant for P values < 0.05.
3.14.2 Paper II 
Statistical analyses were performed using the SigmaStat (v 11.00) package (SPSS, 
Inc., IL, USA) and R statistical software [117]. Mann–Whitney U test was used 
to compare follicle densities, follicle and oocyte nucleus diameters, steroid con-
centrations,	fibrotic	areas,	TUNEL	signal	and	γH2AX	foci	numbers	between	the	
groups.	χ2 test was used to compare the proportions of different follicle classes 
between the groups. Correlation between the morphological measures, age, CED, 
DIE and steroid concentrations was performed using Spearman’s rank correlation. 
Forward stepwise regression analysis was used for the evaluation of the major 
predictor when more than one variable correlated with morphological measures. 
Results are shown as medians and interquartile range. Differences were considered 
statistically significant for P values < 0.05.
3.14.3 Paper III
Statistical analyses were performed using the SigmaStat (v 11.00) package (SPSS, 
Inc., IL, USA), SPSS statistical software (v 25.0) and R statistical software [118]. 
Mann-Whitney U test or Student’s t-test were used to compare continuous vari-
ables between groups, after performing Shapiro-Wilk test for normal distribution. 
Fisher’s	exact	test	and	χ2 test were used for comparison of categorical variables. 
ANOVA on ranks was used to compare the time from OTC indication to OTC 
execution for different diagnoses, indication for OTC and Tanner stage at OTC. 
Spearman’s rank correlation was used to analyze the association between time 
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from OTC indication to OTC execution, age at diagnosis, chemotherapy expo-
sures before OTC in malignant cases and between hormonal measurements, age 
at gonadotoxic treatment, time from gonadotoxic treatment, chemotherapy and 
radiotherapy exposures. Overall survival (OS) was defined as time from gonado-
toxic treatment until date of death or until December 1st, 2019 for survivors, and 
illustrated using the Kaplan-Meier method [119]. Differences in the OS between 
patients with OTC performed and not performed were tested with the log-rank test. 
Time to HRT was defined as the number of years between gonadotoxic treatment 
and HRT start, for patients treated with HRT, and between gonadotoxic treatment 
and December 1st, 2019 for those who did not receive HRT. The cumulative inci-
dence of HRT was illustrated using Kaplan-Meier curves. The association between 
Tanner stage at OTC, age at OTC, chemotherapy and radiotherapy exposures, and 
time to HRT was evaluated using Cox proportional hazards models. The differ-
ences in cumulative incidence of HRT between prepubertal and pubertal patients 
at OTC were tested using the log-rank test.
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4 RESULTS AND DISCUSSION
4.1 Uteroplacental insufficiency affects follicles and 
gene expression in the rat ovary (Paper I)
Placental insufficiency is the common denominator of different diseases that can 
complicate human pregnancies. Placental insufficiency is characterized by a reduced 
placental flow that results in a low blood supply to the fetus and intrauterine growth 
restriction (IUGR). The fetal period is a very sensitive window of development 
when the formation and maturation of organs takes place and gametogenesis is 
established. Some studies suggest that IUGR can affect the ovarian follicles and 
alter pubertal milestones but the evidence is inconclusive. Therefore, we inves-
tigated the impact of IUGR in a rat model of placental insufficiency induced by 
uterine arteries ligature on the ovarian follicle density and gene expression profile.
4.1.1 Decreased follicle density in the ovaries of IUGR rats
IUGR rats had a significantly lower body weight at 5 dpp compared to sham 
rats. At 20 dpp body weight became comparable to that of sham rats, as a result 
of catch-up growth. At 5 dpp, PFs and total follicle density tended to be lower 
in IUGR rats as compared to controls, although the comparison did not reach 
statistical significance. At 20 dpp, PFs and total follicles densities were signifi-
cantly reduced in the ovaries of IUGR rats compared to sham, but this difference 
was no longer present at 40 dpp. The ratio between growing follicles (primary, 
secon dary and tertiary) and total follicles was evaluated as indirect measure of an 
increased activation of PFs. No difference was detected in the ratio between the 
groups at any age. Ovarian weight (both simple and normalized to body weight) 
and ovarian volumes were not different between the groups at any age. Corpora 
lutea number, as indirect measure of ovulation, was also not different between 
IUGR and sham animals. 
Our study is the first exploring the impact of IUGR on the ovary in a rat model 
of placental insufficiency throughout postnatal development. We found that the 
IUGR phenotype was associated with a reduction of PFs at birth that persisted 
until 20 dpp and was no longer evident at 40 dpp, when normalization of the body 
weight had occurred. These findings are in partial agreement with a previous study 
from Engelbregt et al. that reported a decrease in total, primordial and growing 
follicles in IUGR rats at the time of their first cycle (~ 40 dpp) [48]. Despite these 
results were obtained using the same animal model as in our study, the uterine 
arteries ligature was performed 2 days earlier (at 17 dpc) and the animals had a 
longer catch-up growth interval before normalization of their weight at ~ 38 dpp. 
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The normalization in follicle number could be explained in the light of the theory 
of two waves of PFs [13] explained before in this thesis. Based on this theory, 
we speculate that the placental insufficiency in our model damaged only the first 
wave of PFs, while PFs from the adult wave were unaffected, possibly protected 
by their dormant status. The first wave is the prevalent population of PFs in the 
ovary until ~3 months of age, and their depletion would have caused the lower 
number of PFs observed at 20 dpp. At 40 dpp, PFs from the adult wave start to 
be activated and gradually become the most prevalent population of follicles in 
the ovary. This dynamic process could account for the comparable amount of fol-
licles between IUGR and control rats observed at that age. This could imply that 
the ovary has a certain capacity to compensate ovarian damages during childhood 
which is lost as soon as the first wave of follicles is exhausted (i.e. after puberty). 
As there are no histological markers to distinguish the two populations of follicles, 
this hypothesis remains unproven.
4.1.2 Altered gene expression in the ovaries of IUGR rats
Among genes involved in the regulation of cell proliferation and apoptosis, 
Proliferation-related Ki67 antigen (MKi67), Proliferating cell nuclear antigen 
(Pcna), Cyclin-dependent kinase inhibitor 1B (Cdkn1b), DNA topoisomerase II 
(Top2a) and Thymidine kinase 1 (Tk1) were significantly downregulated in IUGR 
rats at 40 dpp. Furthermore, IUGR animals showed a downregulation of genes 
belonging to the insulin-like growth factor (IGF) system, whose components are 
fundamental growth factors in the ovary. In particular, a lower expression of IGF-I 
receptor (Igf1r) both at 20 and 40 dpp, and an increased expression of IGF bind-
ing protein (Igfbp3) at 40 dpp were detected in IUGR animals. Altogether, these 
findings point towards a lower proliferation that could interest both germ and 
somatic cell in the ovary and could reflect hypothetically a lower activation rate 
of PFs, to compensate the PFs loss induced by placental insufficiency during fetal 
life. In parallel to this, the downregulation of Transforming growth factor beta 2 
(Tgfb2) expression at 20 dpp and of Caspase 9 (Casp9) at 40 dpp could negatively 
regulate follicle depletion, lowering the rate at which follicles are physiologically 
depleted during postnatal life and providing a further compensatory mechanism.
4.2 First-line chemotherapy affects follicles and ovarian 
stroma in the human ovary (Paper II)
OTC is offered to patients at high risk of POI based on the planned treatment. 
However, many patients will receive low/medium risk therapies as initial treatment 
of their cancer disease (first-line treatment) before shifting to high risk or second 
line treatments and will therefore be exposed to several cycles of conventional 
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chemotherapy before OTC is performed. Reports on the impact of chemotherapy 
on the quality of ovarian tissue in pediatric and young adult populations are limited 
[61, 62, 81-83, 120, 121]. Therefore, we investigated the impact of chemotherapy 
exposure on quantitative and qualitative measures of preantral follicle health and 
on the ovarian stroma in a cohort of young cancer patients who received OTC 
in comparison to patients who were not exposed to any treatment before OTC. 
Some issues in our paper II were discussed by Shapira et al. [122] and responded 
to by us in the appendix to paper II.
4.2.1 Altered follicle density and size of ovarian follicles in the 
ovaries of cancer patients exposed to chemotherapy
A higher density of atretic primordial and intermediary follicles and a lower density 
of intact primary follicles were found in exposed patients compared to non-exposed 
ones. In exposed patients, intact primordial follicle and oocyte nucleus diameters 
were significantly smaller compared to those of non-exposed ones. Intact inter-
mediary follicles had also a significantly lower follicle diameter in exposed patients.
These findings could indicate that the follicles that survive after exposure to 
chemotherapy are nevertheless affected by the treatment (reduced dimensions of 
intact follicles in the earliest stages) and have a lower maturation potential (lower 
density of primary follicles). A lower maturation potential was already reported 
after culture of ovarian tissues exposed to chemotherapy [83]. Both CED and DIE 
showed a direct association with the reduced diameters of primordial and inter-
mediary follicles and with the lower density of primary follicles. 
4.2.2 Reduced steroid hormone production during culture from 
ovarian tissues of patients exposed to chemotherapy
To evaluate the effects of chemotherapy on the functionality of ovarian tissue, we 
quantified the production of steroid hormones in the media of previously cultured 
ovarian samples, cryopreserved from exposed and non-exposed patients. Estradiol, 
androstenedione,	17α-OH-progesterone,	dehydroepiandrosterone,	testosterone	and	
progesterone were significantly lower in exposed patients compared to non-exposed 
ones. Similar findings were also reported in another study, in which estradiol 
production was reduced in cultured tissues from adult patients who had received 
chemotherapy [123]. Steroid hormones in our media samples could be produced by 
pre-antral follicles or by stromal cells. Therefore, our findings of reduced steroid 
production could reflect both a functional damage to residual pre-antral follicles 
and/or a damage to the stromal compartment after exposure to chemotherapy, as 
detailed in the following paragraph.
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4.2.3 Increased collagen deposition and DNA fragmentation in 
ovarian stroma of patients exposed to chemotherapy
Trichrome assay was used to detect newly formed collagen-rich areas of connec-
tive tissue, representing fibrotic areas in the stromal compartment of the ovary. 
Patients exposed to chemotherapy showed significantly larger areas of collagen 
than non-exposed ones and with a higher degree of intensity. DNA fragmentation, 
evaluated by TUNEL staining, was increased in the stroma of exposed patients 
compared to non-exposed ones. However, 2 out of 7 exposed patients had low levels 
of TUNEL signal, comparable to that of non-exposed ones, which smoothed the 
difference when statistical analysis was performed. After these two patients were 
removed from the analysis, the comparison between exposed and non-exposed 
became statistically significant. Stromal apoptosis has been detected after expos-
ing stromal cells derived from cryopreserved ovarian tissues to doxorubicin and 
cisplatin [124]. Stromal fibrosis and damage to the microvasculature have been 
reported as additional mechanisms responsible for the PFs loss induced by chemo-
therapy [64, 125, 126]. Ovarian stromal cells express steroidogenic enzymes and 
a dysregulated synthesis of steroid hormones from these cells might contribute to 
the pathogenesis of different conditions, such as ovarian tumors and PCOs [127, 
128]. However, a physiological function of stromal-derived steroid hormones has 
not yet been identified. Stromal cells are also the source for recruitment of theca 
cells around early follicle, which is an essential step for follicle development [129]. 
Implications of a compromised stromal compartment might therefore be wider. 
4.2.4 No increase in primordial follicle activation nor in oocyte 
DNA fragmentation in ovaries of patients exposed to 
chemotherapy
Massive PF activation followed by apoptosis, defined as ‘burn-out’ hypothesis, has 
been proposed as a mechanism for the depletion of the ovarian reserve induced by 
chemotherapy [66]. We evaluated PF activation by two measures: the ratio between 
intact growing follicles and total follicles (PFs + growing) and the localization of 
FOXO3A in PFs. In contrast to what expected in case of increased activation, the 
ratio growing/total follicles was decreased in exposed patients compared to non-
exposed patients, suggesting a decreased activation of PFs, which is in line with the 
reduced density of intact primary follicles observed in the ovaries of these patients. 
FOXO3A, which is translocated from the nucleus to the cytoplasm when a PF is 
activated, was expressed in the nucleus of all the intact PFs evaluated, regardless 
of the exposure to chemotherapy. While growing follicles/total follicles ratio is 
a solid morphological measure of PF activation [66], FOXO3A results should be 
interpreted cautiously. Ovarian tissues were harvested 7-55 days after exposure 
to chemotherapy, when detectable signs of follicle activation could have already 
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vanished. DNA fragmentation was explored in the oocyte nuclei by staining for 
phosphorylated	H2AX	(γH2AX).	No	difference	in	the	amount	of	γH2AX	was	
observed between exposed and non-exposed cases. Again, the timing of sample 
collection after treatment exposure could justify the lack of difference, as phos-
phorylation of H2AX is an early phenomenon after DNA damage [130-132]. 
In summary, exposure to first-line chemotherapy before OTC caused significant 
alterations in the quality of ovarian tissue, both on morphological and functional 
parameters. Ovarian tissues harvested after exposure to chemotherapy are widely 
used for restoration of fertility by reimplantation in various centers worldwide. 
However, as discussed in the appendix to paper II, there are no reports on CED 
exposure in relation to parameters of efficacy after reimplantation (i.e. pregnancy 
rates, duration of the functionality of the transplanted tissue). Furthermore, only 
two published cases reported restoration of fertility after reimplantation of ovar-
ian tissue stored during childhood/adolescence and in none of them the patients 
were exposed to chemotherapy before OTC. Moreover, exposure to chemotherapy 
before OTC could lower the in vitro maturation potential of follicles [81, 83, 
84], a strategy of great importance for fertility restoration when reimplantation is 
contraindicated for the risk of malignant contamination. Setting-up OTC is not 
straightforward and limiting the procedure before start of chemotherapy would not 
be a realistic end point. However, it is of vital importance to concentrate efforts 
in reducing unnecessary delays in the execution of OTC.
4.3 Patients at high risk of infertility are correctly 
 identified by selection criteria but fruition rate 
and timing of otc are not optimal (Paper III)
In pediatric settings, OTC is indicated when there is a high (> 50%) or very high 
(> 80%) estimated risk of infertility based on the treatments planned for a certain 
disease. Continuous monitoring of follow-up data is essential in order to verify the 
efficacy of OTC selection criteria, especially in pediatric patients, whose outcomes 
in terms of ovarian function become evident years after the treatment. Furthermore, 
analysis of the modalities by which OTC service is performed allows to identify 
critical issues and adopt corrective strategies.
We analyzed pubertal development and need for hormonal replacement therapy 
in a cohort of patients eligible for OTC between 2002 and 2019 at the Helsinki 
Children’s Hospital. We also evaluated the fruition rate of OTC service and the 
timing required to perform OTC after the indication was established. Our aims were 
i) to analyze if the selection criteria in use in Nordic countries target the patients 
at high risk of infertility, ii) to identify the factors that influence OTC execution, 
timing and extent of chemotherapy exposure.
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4.3.1 Fruition rate and timing of OTC
Between 2002 and 2019, 44% of all eligible patients received OTC at Helsinki 
Children’s Hospital (90/206). The proportion of patients who received OTC 
increased from 35% to 47% during time, possibly indicating an improvement of 
the service. Different referral centers did not affect the proportion of performed 
OTC. Patients who received OTC were comparable to those who did not receive 
it in terms of age and pubertal stage at the time of treatment, diagnosis and indica-
tion to OTC and survival rate. A sub-analysis of patients who underwent HSCT, 
revealed that OTC was performed more frequently if the conditioning regimen 
contained TBI than if it did not contain TBI. Clinician’s perception of an increased 
risk of infertility for patients exposed to TBI could have influenced this result. 
Moreover, a significantly higher proportion of OTC was performed in patients who 
had a matched unrelated donor (MUD) for allogenic HSCT than in those with a 
matched related donor (MRD). HSCT from MUD usually require longer time to 
be organized, which could facilitate setting up OTC procedure. 
Timing of OTC, i.e. time from when the indication was established until OTC was 
performed, was significantly longer in malignant diseases than in non-malignant 
ones. Among malignant conditions, timing of OTC was significantly longer in 
metastatic diseases as compared to relapsed cases. Patients with metastatic diseases 
(mostly neuroblastomas and Ewing sarcomas) undergo several courses of induc-
tion chemotherapy followed by surgery or radiation on the tumor mass. After this, 
patients receive high-dose consolidation chemotherapy followed by autologous 
HSCT. In these patients OTC is probably often combined with the operation to 
remove the tumor mass, or with the CVC positioning performed later on. This 
justify a delay in OTC of several weeks from the diagnosis. On the other hand, 
relapsed cases in our series were mostly represented by hematological malignan-
cies and for these patients preparation for HSCT starts immediately after diagnosis 
of the relapse, providing a shorter window to set up OTC.
In agreement with this hypothesis, patients with metastatic diseases had a sig-
nificantly higher CED exposure before OTC and a significant direct association 
between CED exposure before OTC and time to OTC emerged in correlation 
analysis. We have previously shown that exposure to first-line chemotherapy 
damage the ovarian tissue and might reduce the quality of the tissue harvested 
for fertility preservation. Based on the results of our analysis, future directions 
in OTC practice should point at performing OTC at the earliest possible time, in 
order to limit chemotherapy exposure. For patients with metastatic diseases, for 
example, it could be more beneficial that OTC is performed earlier as a separate 
procedure rather than it is postponed to combine it with the primary operation. 
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4.3.2 Pubertal development and need for hormonal replacement 
therapy (HRT)
Forty patients were selectable for analysis of pubertal development and need of 
HRT. The 50% of them (20/40) needed HRT during follow-up after gonadotoxic 
treatment. Reasons for HRT prescription were induction or maintenance of pubertal 
development, primary or secondary amenorrhea. We divided the 40 patients based 
on their pubertal status at OTC and analyzed the frequency of HRT administration: 
HRT was necessary for 46% of patients who were prepubertal at OTC (11/24) and 
for 56% of those that were pubertal at OTC (9/16).
The cumulative incidence of HRT reached 61% 10 years after the gonadotoxic treat-
ment (HSCT or abdominal irradiation) and it was significantly higher in patients 
that were pubertal at OTC compared to prepubertal ones. After correction for age 
as a confounding factor, pubertal stage was no longer significant and age at OTC 
appeared as the main factor accounting for the increase of the cumulative incidence 
of HRT. These results are in agreement with the well-documented physiological 
decline of PFs, that makes older patients more susceptible of premature ovarian 
insufficiency after gonadotoxic damage [6, 133, 134]. 
In agreement with the literature [115, 135-137], we observed a higher proportion 
of HRT administration in patients treated with irradiation involving the ovarian 
field and with high doses of alkylating agents. Sixty percent of patients exposed to 
irradiation with ovaries in the field (17/29) needed HRT during follow-up. Among 
patients treated with chemotherapy-based regimens and no irradiation to the ovarian 
field (11) only 3 out of 11 (~30%) required HRT during follow-up. The low num-
ber of patients in this group did not allow a statistical determination of the impact 
of different doses of alkylating agents on the risk of needing HRT. However, the 
3/11 patients that needed HRT in this group had received CED > 20 g/m2, whereas 
none of the patients exposed to CED < 20 g/m2 (5/11) needed HRT during follow-
up. Furthermore, patients treated with CED above 20 g/m2 (6/11) had significantly 
higher levels of FSH and significantly lower levels of AMH than patients exposed 
to CED below 20 g/m2.
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5 CONCLUSIONS
In this thesis, we investigated the consequences of two pathological events on 
different measures of ovarian health. In the first study, we analyzed the impact of 
a reduced blood flow to the fetus and intra-uterine growth restriction (IUGR) on 
ovarian development. For this purpose, we evaluated ovarian follicles and gene 
expression in the ovaries of IUGR rats born after surgically-induced placental insuf-
ficiency. In the second study, we aimed at defining the effects of chemotherapy 
treatment received before fertility preservation on the quality of ovarian tissues. 
Ovarian follicles and stromal compartment were investigated in the ovaries of young 
patients exposed to gonadotoxic treatment before undergoing fertility preservation. 
Finally, we analyzed the fertility preservation service in a large pediatric oncology 
unit in terms of appropriateness of selection criteria and performance of the service. 
Ovarian function of young patients who received ovarian tissue cryopreservation 
(OTC) during follow-up was evaluated as a measure of the appropriateness of 
indications for fertility preservation. Fruition rate and timing of OTC in relation 
to chemotherapy exposure before fertility preservation were analyzed.
The main conclusions are listed below:
• IUGR following placental insufficiency reduced primordial and total follicle 
count in the ovaries of neonate and juvenile rats. Follicle count was no longer 
reduced in peripubertal rats, alongside with the recovery of body weight. The 
expression of 24 genes was modified in IUGR rat ovaries, with a potential 
compensatory significance. However, the long-term course and consequences 
of these genetic alterations remain to be elucidated. 
• Exposure to chemotherapy before OTC increased the amount of atretic follicles, 
reduced the size of residual intact follicles in the earliest stages of development 
(primordial and intermediary) and reduced the amount of intact follicles at more 
advanced stages of development (primary follicles). The secretion of steroid 
hormones from cultured ovarian tissue pieces was reduced and ovarian stroma 
was significantly damaged by exposure to chemotherapy before OTC. 
• The implementation of selection criteria for OTC was not optimal and the fruition 
rate for eligible patients was around the 50%. A fraction of patients are excluded 
from OTC because of their clinical conditions, which is a non-modifiable 
factor. Interventions should focus on controllable factors (such as appropriate 
counselling to the parents and the patients) aiming at increasing the fruition 
rate of this fundamental service. The timing of OTC was longer for patients 
with malignant diseases, in particular those affected by cancers in metastatic 
stage. A longer time before OTC increases the exposure to chemotherapy, thus 
lowering the quality of the ovarian tissue harvested for fertility preservation. 
Optimal slots for OTC should be defined for the different indications in order 
to implement the guidelines.
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• OTC execution should be prioritized, compatibly with clinical conditions, 
and all efforts should be done to limit unnecessary exposure to chemotherapy 
before OTC and guarantee the best quality of the ovarian tissue harvested for 
fertility preservation. 
• Fifty percent of the patients who received OTC needed hormonal replacement 
therapy during a follow-up of more than 10 years, a figure set to increase with 
time. Hence, our conclusion is that the selection criteria for fertility preserva-
tion adopted by Nordic Countries correctly identify the patients at high risk 
of infertility. We suggest that these guidelines are implemented with specific 
considerations about the age of the patient. Older patients are at increased 
risk of infertility than younger ones for a given gonadotoxic treatment. It is 
therefore essential that these patients get access to the service and in a short time 
frame from when the indication is established. This precaution would prevent 
unnecessary exposure to chemotherapy that we proved to be detrimental for 
the quality of the harvested ovarian tissues. 
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